Guangxi Huaxi Nonferrous Metal (600301.SH) announces forecasted increase in net profit for 2024, estimated to be between 6.1 billion to 6.8 billion yuan, representing a year-on-year growth of 94.56% to 116.89%.
HuaXi Nonferrous (600301.SH) issued an announcement, expecting to achieve a net profit attributable to the parent company owner in 2024...
Guangxi Huaxi Nonferrous Metal (600301.SH) announced that it is expected to achieve a net profit attributable to the owners of the parent company of 610 million yuan to 680 million yuan in 2024. Compared with the same period last year (statutory disclosure data), it will increase by 2964.78 million yuan to 3664.78 million yuan, with a growth rate of 94.56% to 116.89%; compared with the same period last year (retrospective adjustment), it will increase by 2783.205 million yuan to 3483.205 million yuan, with a growth rate of 83.91% to 105.02%.
It is expected that the net profit attributable to the owners of the parent company excluding non-recurring gains and losses will be 590 million yuan to 650 million yuan in 2024. Compared with the same period last year, it will increase by 2694.87 million yuan to 3294.87 million yuan, with a growth rate of 84.08% to 102.80%.
Related Articles

JINHAI MED TECH (02225) announced its annual performance, with a net loss of 17.08 million Singapore dollars attributable to shareholders, a decrease of 4.9% year-on-year.

RIZHAO PORT JR (06117) Announces Annual Performance Net Profit of 171 million RMB Decreased by 17.03% Year-on-Year.

SICC Co., Ltd. (02631) achieved a total revenue of approximately 1.465 billion yuan in 2025, continuing to increase research and development expenses to consolidate its leading position in the industry against the trend.
JINHAI MED TECH (02225) announced its annual performance, with a net loss of 17.08 million Singapore dollars attributable to shareholders, a decrease of 4.9% year-on-year.

RIZHAO PORT JR (06117) Announces Annual Performance Net Profit of 171 million RMB Decreased by 17.03% Year-on-Year.

SICC Co., Ltd. (02631) achieved a total revenue of approximately 1.465 billion yuan in 2025, continuing to increase research and development expenses to consolidate its leading position in the industry against the trend.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


